In spite of the well-described effects of SCF on erythropoiesis, clinical attempts to use this growth factor for the treatment of EPO-unresponsive anemias have not been encouraging so far and an international trial in Diamond Blackfan Anemia was prematurely interrupted by the National Institute of Health after the death of one patient (58). This evidence concerns the gene EPO and anemia.